Median Technologies is an oncology-focused imaging company that provides iCRO centralized imaging services for oncology clinical trials, machine-learning-enabled imaging analytics for biomarker discovery, and the eyonis® AI software-as-a-medical-device suite for lung cancer screening (pending regulatory clearance).
Published Sep 29, 2026
Median cites operational experience across many studies and sites but does not publicly provide key operational KPIs such as turnaround-time distributions, query rates, re-read/adjudication frequencies, or inspection/audit outcomes.
Get a comprehensive analysis of Median Technologies including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →If your procurement policy requires publicly documented security certifications (SOC 2 / ISO 27001) before contracting. Public materials reviewed did not show these certifications; vendors that publish these artifacts may simplify procurement.
If you need a mature, widely deployed clinical diagnostic product immediately for lung screening. eyonis® LCS is under regulatory review and not commercially available in jurisdictions referenced in the public materials.
If you rely heavily on public third-party customer reviews for vendor selection. Median’s iCRO services are not well represented on SaaS review platforms; validating service quality may require reference calls and additional diligence.
If your trial is non-oncology and requires a broad multi-therapeutic imaging core lab. Median emphasizes oncology specialization; broader providers may be a better default.
Median’s offerings are primarily clinical trial services and regulated medtech software under development, which typically have:
Result: There were no clearly attributable G2/Capterra product review pages for "Median Technologies iCRO" or "eyonis®" found in the searches performed. This is a gap for buyers who expect extensive peer review data.
Because public customer reviews for the product are scarce, the closest available public sentiment signals are:
Public pages were primarily corporate descriptions and press releases rather than detailed case studies with independent validation.
Example: eyonis® LCS pivotal studies (vendor-reported)
Critical evaluation:
Median Technologies is an oncology-focused imaging company with two major lines of business:
Objective framing: Median provides operational trial imaging execution and analytic services (radiomics/biomarker discovery, advanced analytics) intended to support drug-development decision-making and, contingent on regulatory outcomes, clinical diagnostic workflows.
Key vendor claims to treat cautiously: The website and investor communications use marketing terms such as "best-in-class" and "world-leading" and report large operational metrics (studies supported, sites, publications). These are self-reported and were not independently audited in the public materials reviewed.
Positioning emphasizes: